Please assess the completion status of the following clinical trial:

Trial Title: Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and understand and comply with the requirements of the study~2. HCV genotype 1 infected null responders to prior therapy comprised of pegylated interferon and ribavirin (standard of care, SOC) defined as:~   * Failure to achieve an early virologic response (\< 2 log decline in HCV-RNA by Week 12), or~  * If Week 12 HCV-RNA was not obtained, post Week 12 HCV-RNA response was \< 2 log decline~3. Screening HCV-RNA viral load of \> 5.0 log (i.e., \>100,000 IU/mL)~4. alpha-fetoprotein (AFP) less than or equal to 100 ng/mL~5. Hemoglobin greater than or equal to 12 g/dL for women and greater than or equal to 13 g/dL for men, hemoglobin A1c less than or equal to 7.5 %, platelet count greater than or equal to 90 x 10\^9/L, and white blood cell count greater than or equal to 1.5 x 10\^9/L~6. Thyroid Stimulating Hormone (TSH) within normal limits~7. In the opinion of the Principal Investigator, the patient met the 80%/80%/80% rule during the previous pegylated interferon and ribavirin therapy (i.e., received at least 80% of the pegylated interferon and ribavirin doses, at least 80% of the dose size, for at least 80% of the treatment duration)~8. Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from screening to at least six months after the completion of the study.~Exclusion Criteria:~1. \< 2 log decline in HCV-RNA at Week 12 but \> 2 log decline at any time from Week 12 to Week 24 during prior therapy with pegylated interferon and ribavirin (prior standard of care therapy)~2. Decompensated or severe liver disease defined by one or more of the following criteria:~   * Prothrombin time 4 seconds \> control or INR (international normalized ratio) \> 1.2~  * Total bilirubin ≥ 1.5 mg/dL or direct bilirubin ≥ 1 mg/dL~  * Serum albumin below normal limits~  * aspartate aminotransferase (AST) or alanine aminotransferase (ALT)\> 5 x upper limit of normal (ULN) at screening~  * Presence of ascites~3. Hepatic encephalopathy~4. Hepatocellular carcinoma (HCC) or suspicion of HCC clinically or on ultrasound (or other imaging techniques)~5. Clinically significant ocular findings such as retinopathy, cotton wool spots, optic nerve disorder, retinal hemorrhage, or other abnormality~6. Known history or presence of human immunodeficiency virus (HIV) infection~7. Co-infection with hepatitis B virus (HBV)~8. If female: pregnant, lactating, or positive serum or urine pregnancy test~9. Male partners of women who are currently pregnant~10. Renal impairment (creatinine \> 1.2 x ULN), serum creatinine clearance \< 50 mL/min, or hepatorenal syndrome with ascites~11. Hospitalization for liver disease within 60 days of screening~12. History of alcohol abuse (\> 50 g per day) within the past year~13. History of severe psychiatric disease, especially depression, characterized by:~    * Suicide attempt~   * Hospitalization for psychiatric disease~   * Period of disability as a result of psychiatric disease~14. Prior exposure to CTS-1027~15. Patients who qualify as a null-responder based on treatment(s) other than pegylated interferon and ribavirin~16. History or presence of clinically concerning cardiac arrhythmias or prolongation of pre-dose corrected Q-T interval (QTc) of \> 450 milliseconds~17. History of or current autoimmune disease~18. Diagnosis of or symptoms suggestive of fibromyalgia~19. Currently on liver transplantation waiting list or recipient of any organ transplant~20. Other concomitant disease or condition likely to significantly decrease life expectancy (e.g., moderate to severe congestive heart failure) or any malignancy other than curatively treated skin cancer (basal cell or squamous cell carcinomas), unless adequately treated or in complete remission for five or more years~21. Exposure to any other investigational treatment for any aspect of disease associated with HCV during the past 6 months~22. Exposure to any investigational drug or device within 30 days of dosing, or scheduled receipt of another investigational drug or device during the course of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CTS-1027 60 mg + ribavirin + peglyated interferon (Type: EXPERIMENTAL): Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027, 60 mg (supplied in a blinded kit containing two bottles of 30 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 120 mg.
- CTS-1027 30 mg + ribavirin + pegylated interferon (Type: EXPERIMENTAL): Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 30 mg, supplied in a blinded kit containing one bottle of 30 mg tablets, and one bottle of placebo tablets (in order to maintain blind). One tablet from each of the bottles is taken twice daily, for a total daily dose of 60 mg of CTS-1027.
- CTS-1027 15 mg + ribavirin + pegylated interferon (Type: EXPERIMENTAL): Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 15 mg (supplied in a blinded kit containing one bottle each of of 5 mg and 10 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 30 mg.
- placebo + ribavirin + pegylated interferon (Type: ACTIVE_COMPARATOR): Standard of Care (ribavirin plus pegylated interferon) plus placebo (supplied in a blinded kit containing two bottles of placebo tablets). One tablet is taken from each of the placebo bottles twice daily, for a total daily dose of 4 tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).